A Randomized Phase II Study of Carboplatin With Weekly or Every-3-Week Nanoparticle Albumin-Bound Paclitaxel (Abraxane) in Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Phase II Study of Carboplatin With Weekly or Every-3-Week Nanoparticle Albumin-Bound Paclitaxel (Abraxane) in Patients With Extensive-Stage Small Cell Lung Cancer
复制标题
DOI：
10.1634/theoncologist.2014-0327
复制
发表时间：
2015-02-01
期刊：
影响因子：
5.8
通讯作者：
Stinchcombe, Thomas E.
中科院分区：
文献类型：
--
作者：
Grilley-Olson, Juneko E.;Keedy, Vicki L.;Stinchcombe, Thomas E.
背景。铂加依托泊苷是广泛期小细胞肺癌 (ES-SCLC) 的标准疗法，并与显着的骨髓抑制相关。我们假设卡铂和纳米颗粒白蛋白结合紫杉醇（nab-紫杉醇）的组合会具有更好的耐受性。我们研究了每 3 周和每周一次的卡铂联合白蛋白结合型紫杉醇的治疗方案。方法。这项非比较性随机 II 期试验采用了两阶段设计。主要目标是客观缓解率，次要目标是无进展生存期、总生存期和毒性。 ES-SCLC 患者和东部肿瘤合作组表现状态
Background. Platinum plus etoposide is the standard therapy for extensive-stage small cell lung cancer (ES-SCLC) and is associated with significant myelosuppression. We hypothesized that the combination of carboplatin and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) would be better tolerated. We investigated carboplatin with nab-paclitaxel on every-3-week and weekly schedules.Methods. This noncomparative randomized phase II trial used a two-stage design. The primary objective was objective response rate, and secondary objectives were progression-free survival, overall survival, and toxicity. Patients with ES-SCLC and an Eastern Cooperative Oncology Group performancestatus